9999999997-18-000397.txt : 20180117
9999999997-18-000397.hdr.sgml : 20180117
20180117104136
ACCESSION NUMBER: 9999999997-18-000397
CONFORMED SUBMISSION TYPE: CT ORDER
PUBLIC DOCUMENT COUNT: 1
FILED AS OF DATE: 20180117
DATE AS OF CHANGE: 20180117
ACTION DATE: 20180117
RECEIVED DATE: 20180117
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: ARGOS THERAPEUTICS INC
CENTRAL INDEX KEY: 0001105533
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 562110007
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: CT ORDER
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35443
FILM NUMBER: 18530473
BUSINESS ADDRESS:
STREET 1: 4233 TECHNOLOGY DR
CITY: DURHAM
STATE: NC
ZIP: 27704
BUSINESS PHONE: 9192876300
MAIL ADDRESS:
STREET 1: 4233 TECHNOLOGY DR
CITY: DURHAM
STATE: NC
ZIP: 27704
FORMER COMPANY:
FORMER CONFORMED NAME: MERIX BIOSCIENCE INC
DATE OF NAME CHANGE: 20000207
CT ORDER
1
filename1.pdf
begin 644 filename1.pdf
M)5!$1BTQ+C4-)>+CS],-"C$P(# @;V)J#3P\+TQI;F5A#0IE;F1S
M=')E86T-96YD;V)J#7-T87)T>')E9@T*, T*)25%3T8-"B @(" @(" @#0HR
M,B P(&]B:@T\/"]&:6QT97(O1FQA=&5$96-O9&4O22 X-"],(#8X+TQE;F=T
M:" V,2]3(#,X/CYS=')E86T-"FC>8F!@8&9@8.)G (.+094P C$+ P<#7!E+T-A=&%L;V<^/@UE;F1O8FH-,3(@
M,"!O8FH-/#PO0V]N=&5N=',@,30@,"!2+T-R;W!";WA;," P(#8Q,B W.3)=
M+TUE9&EA0F]X6S @," V,3(@-SDR72]087)E;G0@." P(%(O4F5S;W5R8V5S
M(#$V(# @4B]2;W1A=&4@,"]4>7!E+U!A9V4^/@UE;F1O8FH-,3,@,"!O8FH-
M/#PO1FEL=&5R+T9L871E1&5C;V1E+T9I\YZ6 @4F 1 XN
M><;%X D.G)J8<0P8-:&;&W)_U@^)EEJ9_4/"L(K"XW1*%E6I32Q-.1:;F-GZ
M6.G@=5WM$J4W9'VW(*DZZ^UT:M*_K>&7S!ME-DM@))FUQV0)]!/E)'TYJ4M/
M4IT<;FMGS4Z5&J*8D5MY^JRRPU$;GI22.^6@"63RT(#G6X;S>77>3((@
M@HE'A9F/FL$I#[<67<@BRU\^I%FA&EBIW_!8%;+\:+&5+!2QB %L?)U,YE6^
M7Z863W2M].Y(5E5=R-R&GAPE81A]T3+/=K/RD"N@)-&J^&[^<^CFPURD7&R%-6SLHFZ\^+K&[T[5'6X/%1%WQH?*2O
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M;V)J#3P\+T9I;'1EJL+BB+I:\;UY?LMXV#A!K@0*;HI EVF:A2"XE
M;9*_[_ BQ?8FVSJ(35+DS)PS9X;Z<+-E<&A&G]+1AS3U@4&Z'S$?//S#GZD'
ML9?0)(3T<>3! ?_37'T]C0@XZ=\CEH#+*(L@7=B5]-?K@1O0Z?1UFTL]CTV5
M'3MX>C7S?K=.FX(9V2!6P=-Z(Q21W*R"PUJTN[",Z?Z9>1.Z%Q'%W:]";6
MIAHHF]OE_.O].ET[N#M$ S#;+ "=!'1"_IA_GFUN[ 3F=[>WZ^UV?;QV<.&>N4Q_;R$GC"D:FD)@MD\A;L5L&F@^/=): UB+L*?8$5_L7_I+E!;
M7#M2CF?R4#>0'KG,3KQK1=Z,85TY$QJ1G!HWZ#'Y":&X]8Q/LA(EATU- ;/D
M!E$8!N#"?/5+$,4),V%1_TR)Y*^W/GHC%D-HBD%19Z46OJK2G4ZER+-6U$Z$DJV@
MJPHNX;Y#R'ZXEB- A>8V%#"IE-88L'G9 &!/):92X@9BH*7K4BPW 8*:&5>I&;>?OH
M3/$'-X#97#OHAD@0U;Z6YJ'"68%H@>LCSWI'7G8%$F4.254QV1=#JK%GJ+"^:?+2K$7O(&L40G=VS26.'E\
MY#)7PUHB;"T.[*J3Z*P9A2;N*JOT1NU8]=X),3HW 1C=J@2L).=%;9XI 5JZ
MC-F!+FQJ%L&@BUG>CB&"KW1+YQ2BR'\@NP?G@80/SEA;7HCOHB^FOI9>:?]&
M>LG/:WFJI3&Z$BIP#D?$7O"6H\>8)D142/Y01_[5G6,N@ZINE8A.W0Y+M'R!
M0C1Y63<-$!$-#N.W1/+2XT9%):RN,=WOJQ*6H"VA./%?:*O2ACX,.KZO!--;P
MLE%A!PZGMG0!^LH%1]<'W(
M5V\@.A;O/ROTAZSU%;JRR.=8)3I;HE$*&ZL*[>5H)=>KLQA==B?REBS'
MR+)LNJS22C-O$]K*19^[BI 4F+%#IF^7KCW64K0O'WM$;X#\<:"O/GW_@/Y\
M4JSYV'S].%2Z4#^8SLJ0V:JY*AI+[A2][B6YF^!=]5V)M __]@F8[^%6 ,:'(B@T*
M96YDG)E4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M
M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!8
M35 @0V]R92 U+C8M8S Q-2 X-"XQ-3DX,3 L(#(P,38O,#DO,3 M,#(Z-#$Z
M,S @(" @(" @("(^"B @(#QR9&8Z4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W
M=RYW,RYO&UL;G,Z<&1F/2)H='1P.B\O;G,N861O8F4N8V]M+W!D9B\Q+C,O(@H@
M(" @(" @(" @("!X;6QN&UP.D-R96%T;W)4;V]L/E!38W)I<'0U+F1L;"!697)S
M:6]N(#4N,BXR/"]X;7 Z0W)E871O&UP34TZ26YS=&%N8V5)1#YU
M=6ED.C=C86-D,C0U+3DT,C&UP
M34TZ26YS=&%N8V5)1#X*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(#PO
MJ'5!:DZ@UCF4@,3 O5'EP
M92]84F5F+U=;,2 R(#%=/CYS=')E86T-"FC>8F( B9&KE,,3 R,;4""=SZ(
MU0LB.($2SVJ + 8&1B#!]!](,#( !!@ ?,\%&PT*96YD